Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child

Makoto Hayashida, Keiko Ogita, Toshiharu Matsuura, Yukiko Takahashi, Yuko Nishimoto, Shouichi Ohga, Toshiro Hara, Yuji Soejima, Akinobu Taketomi, Yoshihiko Maehara, Kenichi Kohashi, Masazumi Tsuneyoshi, Tomoaki Taguchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PTLD is a serious complication of immunosuppression in solid organ transplant recipients. The incidence of PTLD is significantly higher in pediatric recipients than in adult because children are often EBV-seronegative and they may develop primary EBV infection after transplantation. We herein describe a case of GI-PTLD who achieved a complete remission by prolonged rituximab, a chimeric monoclonal antibody against CD20, mono-therapy. A one-yr-old female underwent a LDLT for liver failure after having previously undergone the Kasai procedure for biliary atresia. At sixty days following the transplantation, GI-PTLD developed. Withdrawal of immunosuppression and a surgical resection were thus performed. A histopathological examination of tumor revealed atypical medium to large cell lymphoid proliferation with strong CD20 immunopositivity indicating their B-cell origin. Polymorphic PTLD was diagnosed. Rituximab was administered at a dose of 375 mg/m2 once a week, and the monotherapy resulted in a complete remission after 34 administrations. Based on this case, rituximab appears to be beneficial as a first-line therapy for PTLD.

Original languageEnglish
Pages (from-to)671-675
Number of pages5
JournalPediatric Transplantation
Volume11
Issue number6
DOIs
Publication statusPublished - Sep 1 2007

Fingerprint

Lymphoproliferative Disorders
Living Donors
Liver Transplantation
Transplants
Immunosuppression
Transplantation
Biliary Atresia
Epstein-Barr Virus Infections
Liver Failure
Human Herpesvirus 4
B-Lymphocytes
Therapeutics
Monoclonal Antibodies
Cell Proliferation
Pediatrics
Incidence
Rituximab
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child. / Hayashida, Makoto; Ogita, Keiko; Matsuura, Toshiharu; Takahashi, Yukiko; Nishimoto, Yuko; Ohga, Shouichi; Hara, Toshiro; Soejima, Yuji; Taketomi, Akinobu; Maehara, Yoshihiko; Kohashi, Kenichi; Tsuneyoshi, Masazumi; Taguchi, Tomoaki.

In: Pediatric Transplantation, Vol. 11, No. 6, 01.09.2007, p. 671-675.

Research output: Contribution to journalArticle

Hayashida, Makoto ; Ogita, Keiko ; Matsuura, Toshiharu ; Takahashi, Yukiko ; Nishimoto, Yuko ; Ohga, Shouichi ; Hara, Toshiro ; Soejima, Yuji ; Taketomi, Akinobu ; Maehara, Yoshihiko ; Kohashi, Kenichi ; Tsuneyoshi, Masazumi ; Taguchi, Tomoaki. / Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child. In: Pediatric Transplantation. 2007 ; Vol. 11, No. 6. pp. 671-675.
@article{2a52a3cde3d44bccbeff4dc54174e7d3,
title = "Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child",
abstract = "PTLD is a serious complication of immunosuppression in solid organ transplant recipients. The incidence of PTLD is significantly higher in pediatric recipients than in adult because children are often EBV-seronegative and they may develop primary EBV infection after transplantation. We herein describe a case of GI-PTLD who achieved a complete remission by prolonged rituximab, a chimeric monoclonal antibody against CD20, mono-therapy. A one-yr-old female underwent a LDLT for liver failure after having previously undergone the Kasai procedure for biliary atresia. At sixty days following the transplantation, GI-PTLD developed. Withdrawal of immunosuppression and a surgical resection were thus performed. A histopathological examination of tumor revealed atypical medium to large cell lymphoid proliferation with strong CD20 immunopositivity indicating their B-cell origin. Polymorphic PTLD was diagnosed. Rituximab was administered at a dose of 375 mg/m2 once a week, and the monotherapy resulted in a complete remission after 34 administrations. Based on this case, rituximab appears to be beneficial as a first-line therapy for PTLD.",
author = "Makoto Hayashida and Keiko Ogita and Toshiharu Matsuura and Yukiko Takahashi and Yuko Nishimoto and Shouichi Ohga and Toshiro Hara and Yuji Soejima and Akinobu Taketomi and Yoshihiko Maehara and Kenichi Kohashi and Masazumi Tsuneyoshi and Tomoaki Taguchi",
year = "2007",
month = "9",
day = "1",
doi = "10.1111/j.1399-3046.2007.00714.x",
language = "English",
volume = "11",
pages = "671--675",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child

AU - Hayashida, Makoto

AU - Ogita, Keiko

AU - Matsuura, Toshiharu

AU - Takahashi, Yukiko

AU - Nishimoto, Yuko

AU - Ohga, Shouichi

AU - Hara, Toshiro

AU - Soejima, Yuji

AU - Taketomi, Akinobu

AU - Maehara, Yoshihiko

AU - Kohashi, Kenichi

AU - Tsuneyoshi, Masazumi

AU - Taguchi, Tomoaki

PY - 2007/9/1

Y1 - 2007/9/1

N2 - PTLD is a serious complication of immunosuppression in solid organ transplant recipients. The incidence of PTLD is significantly higher in pediatric recipients than in adult because children are often EBV-seronegative and they may develop primary EBV infection after transplantation. We herein describe a case of GI-PTLD who achieved a complete remission by prolonged rituximab, a chimeric monoclonal antibody against CD20, mono-therapy. A one-yr-old female underwent a LDLT for liver failure after having previously undergone the Kasai procedure for biliary atresia. At sixty days following the transplantation, GI-PTLD developed. Withdrawal of immunosuppression and a surgical resection were thus performed. A histopathological examination of tumor revealed atypical medium to large cell lymphoid proliferation with strong CD20 immunopositivity indicating their B-cell origin. Polymorphic PTLD was diagnosed. Rituximab was administered at a dose of 375 mg/m2 once a week, and the monotherapy resulted in a complete remission after 34 administrations. Based on this case, rituximab appears to be beneficial as a first-line therapy for PTLD.

AB - PTLD is a serious complication of immunosuppression in solid organ transplant recipients. The incidence of PTLD is significantly higher in pediatric recipients than in adult because children are often EBV-seronegative and they may develop primary EBV infection after transplantation. We herein describe a case of GI-PTLD who achieved a complete remission by prolonged rituximab, a chimeric monoclonal antibody against CD20, mono-therapy. A one-yr-old female underwent a LDLT for liver failure after having previously undergone the Kasai procedure for biliary atresia. At sixty days following the transplantation, GI-PTLD developed. Withdrawal of immunosuppression and a surgical resection were thus performed. A histopathological examination of tumor revealed atypical medium to large cell lymphoid proliferation with strong CD20 immunopositivity indicating their B-cell origin. Polymorphic PTLD was diagnosed. Rituximab was administered at a dose of 375 mg/m2 once a week, and the monotherapy resulted in a complete remission after 34 administrations. Based on this case, rituximab appears to be beneficial as a first-line therapy for PTLD.

UR - http://www.scopus.com/inward/record.url?scp=34547477604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547477604&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2007.00714.x

DO - 10.1111/j.1399-3046.2007.00714.x

M3 - Article

C2 - 17663692

AN - SCOPUS:34547477604

VL - 11

SP - 671

EP - 675

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 6

ER -